|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM219 |
Gene summary for TMEM219 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM219 | Gene ID | 124446 |
| Gene name | transmembrane protein 219 | |
| Gene Alias | IGFBP-3R | |
| Cytomap | 16p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | A0A024R618 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 124446 | TMEM219 | CA_HPV_1 | Human | Cervix | CC | 7.34e-09 | -2.20e-01 | 0.0264 |
| 124446 | TMEM219 | CCI_1 | Human | Cervix | CC | 2.52e-04 | -4.97e-01 | 0.528 |
| 124446 | TMEM219 | CCI_3 | Human | Cervix | CC | 1.42e-05 | -5.09e-01 | 0.516 |
| 124446 | TMEM219 | CCII_1 | Human | Cervix | CC | 8.82e-14 | -5.82e-01 | 0.3249 |
| 124446 | TMEM219 | Tumor | Human | Cervix | CC | 1.02e-02 | -2.04e-01 | 0.1241 |
| 124446 | TMEM219 | L1 | Human | Cervix | CC | 4.01e-02 | -9.36e-02 | 0.0802 |
| 124446 | TMEM219 | T3 | Human | Cervix | CC | 1.15e-03 | -2.46e-01 | 0.1389 |
| 124446 | TMEM219 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.09e-18 | 4.41e-01 | 0.0155 |
| 124446 | TMEM219 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.03e-25 | 8.51e-01 | -0.1808 |
| 124446 | TMEM219 | HTA11_2951_2000001011 | Human | Colorectum | AD | 5.21e-03 | 5.88e-01 | 0.0216 |
| 124446 | TMEM219 | HTA11_1938_2000001011 | Human | Colorectum | AD | 7.56e-17 | 7.76e-01 | -0.0811 |
| 124446 | TMEM219 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.02e-14 | 5.06e-01 | -0.1088 |
| 124446 | TMEM219 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.48e-42 | 8.59e-01 | -0.1954 |
| 124446 | TMEM219 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.02e-13 | 1.07e+00 | -0.2602 |
| 124446 | TMEM219 | HTA11_2112_2000001011 | Human | Colorectum | SER | 2.37e-07 | 7.93e-01 | -0.2196 |
| 124446 | TMEM219 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.67e-13 | 6.81e-01 | -0.1207 |
| 124446 | TMEM219 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.59e-16 | 7.40e-01 | -0.1526 |
| 124446 | TMEM219 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.10e-34 | 8.22e-01 | -0.1464 |
| 124446 | TMEM219 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.69e-22 | 5.83e-01 | -0.1001 |
| 124446 | TMEM219 | HTA11_1391_2000001011 | Human | Colorectum | AD | 9.95e-33 | 8.46e-01 | -0.059 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM219 | SNV | Missense_Mutation | c.462N>A | p.Ser154Arg | p.S154R | Q86XT9 | protein_coding | tolerated(0.14) | possibly_damaging(0.814) | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| TMEM219 | SNV | Missense_Mutation | c.463N>G | p.Gln155Glu | p.Q155E | Q86XT9 | protein_coding | tolerated(0.35) | possibly_damaging(0.479) | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| TMEM219 | SNV | Missense_Mutation | novel | c.649N>T | p.Gly217Cys | p.G217C | Q86XT9 | protein_coding | tolerated(0.07) | probably_damaging(1) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| TMEM219 | SNV | Missense_Mutation | c.143N>C | p.Leu48Pro | p.L48P | Q86XT9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| TMEM219 | SNV | Missense_Mutation | novel | c.253N>A | p.Val85Ile | p.V85I | Q86XT9 | protein_coding | tolerated(0.22) | benign(0) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TMEM219 | SNV | Missense_Mutation | novel | c.359N>A | p.Ser120Tyr | p.S120Y | Q86XT9 | protein_coding | tolerated(0.11) | possibly_damaging(0.628) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TMEM219 | SNV | Missense_Mutation | rs761299676 | c.692N>A | p.Arg231Gln | p.R231Q | Q86XT9 | protein_coding | tolerated(0.06) | benign(0.003) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM219 | SNV | Missense_Mutation | novel | c.451C>A | p.Leu151Ile | p.L151I | Q86XT9 | protein_coding | deleterious(0.03) | probably_damaging(0.994) | TCGA-AJ-A3NE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM219 | SNV | Missense_Mutation | rs766765480 | c.221N>A | p.Gly74Glu | p.G74E | Q86XT9 | protein_coding | tolerated(1) | benign(0.001) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| TMEM219 | SNV | Missense_Mutation | novel | c.300G>T | p.Arg100Ser | p.R100S | Q86XT9 | protein_coding | tolerated(0.15) | benign(0.022) | TCGA-21-1083-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |